Alignment Healthcare (NASDAQ:ALHC) Insider Christopher Joyce Sells 16,187 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Christopher Joyce sold 16,187 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $18.74, for a total value of $303,344.38. Following the completion of the transaction, the insider owned 307,699 shares of the company’s stock, valued at approximately $5,766,279.26. This represents a 5.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alignment Healthcare Trading Up 1.6%

Shares of ALHC opened at $19.24 on Wednesday. Alignment Healthcare, Inc. has a twelve month low of $11.01 and a twelve month high of $21.06. The stock has a market cap of $3.85 billion, a PE ratio of -160.33 and a beta of 1.16. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99. The business’s 50-day moving average price is $18.22 and its 200-day moving average price is $16.22.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. Alignment Healthcare had a negative net margin of 0.57% and a negative return on equity of 16.23%. The company had revenue of $993.70 million during the quarter, compared to analysts’ expectations of $980.90 million. During the same quarter in the previous year, the company earned ($0.14) earnings per share. Alignment Healthcare’s revenue for the quarter was up 43.5% on a year-over-year basis. On average, equities analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

More Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Baird published a note saying Alignment Healthcare “should be bought on recent selloff,” which can attract value-oriented buyers and help lift the stock. Baird Buy Note
• Negative Sentiment: CEO John E. Kao sold 605,648 shares at an average price of $18.74 (~$11.35M), a 21.33% reduction in his holding — a large, high‑profile insider sale that can be read as a negative signal for sentiment. Kao SEC Filing
• Negative Sentiment: President Dawn Christine Maroney sold 282,070 shares at $18.74 (~$5.29M), cutting her stake by ~16.9% — another sizable insider disposition that can weigh on investor confidence. Maroney SEC Filing
• Negative Sentiment: Other insider sales include Robert L. Scavo (69,541 shares), Christopher J. Joyce (16,187 shares) and Hyong Kim (12,694 shares), each sold at $18.74 — smaller individually but collectively add to the sell-side signal. Scavo SEC Filing Joyce SEC Filing Kim SEC Filing

Hedge Funds Weigh In On Alignment Healthcare

Several institutional investors have recently modified their holdings of ALHC. Wellington Management Group LLP raised its holdings in shares of Alignment Healthcare by 167.3% during the 3rd quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock valued at $193,516,000 after buying an additional 6,940,277 shares in the last quarter. Invesco Ltd. raised its stake in shares of Alignment Healthcare by 122.3% during the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after acquiring an additional 2,294,739 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Alignment Healthcare by 173.3% in the 2nd quarter. Marshall Wace LLP now owns 2,039,714 shares of the company’s stock worth $28,556,000 after acquiring an additional 1,293,416 shares during the last quarter. Voya Investment Management LLC boosted its stake in shares of Alignment Healthcare by 61.0% in the 3rd quarter. Voya Investment Management LLC now owns 3,196,297 shares of the company’s stock valued at $55,775,000 after purchasing an additional 1,210,930 shares in the last quarter. Finally, Integral Health Asset Management LLC boosted its stake in shares of Alignment Healthcare by 300.0% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,600,000 shares of the company’s stock valued at $27,920,000 after purchasing an additional 1,200,000 shares in the last quarter. 86.19% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. The Goldman Sachs Group reissued a “buy” rating and set a $22.00 price objective on shares of Alignment Healthcare in a research note on Monday, November 3rd. Zacks Research downgraded Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th. UBS Group boosted their price objective on Alignment Healthcare from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. JPMorgan Chase & Co. raised their target price on shares of Alignment Healthcare from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Finally, Wall Street Zen upgraded shares of Alignment Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.35.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.